Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

TSXV:CLAS.H - Post Discussion

Claritas Pharmaceuticals Inc > Ex #3 - Barda just gave SRI $ 90 MIL for testing capability
View:
Post by Looking4Doubles on Jun 11, 2020 2:01pm

Ex #3 - Barda just gave SRI $ 90 MIL for testing capability

Barda contract for addl TESTING capabilities
Comment by JMark80 on Jun 11, 2020 2:33pm
That contract is 3 years old. Other two involve vaccines.
Comment by Looking4Doubles on Jun 11, 2020 2:38pm
My point is that Barda does a LOT of things and the talk in the U.S. is for far-ranging efforts, NOT just vaccines The OTHER TWO?  - You need to RE-read them, not just the titles (one for Viles, one for packaging tech.)
Comment by JMark80 on Jun 11, 2020 2:42pm
Viles and packaging, for vaccines. Good talk, later boners!
Comment by Looking4Doubles on Jun 11, 2020 2:44pm
Ha ha ha ha  - Showing your true colors JMark
Claritas Pharmaceuticals Inc